ArticleBiomedicines2022

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype.

Ruperto González-Pérez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.